Vaccitech Ltd, an Oxford, UK – based clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, raised $168m in Series B financing.
The round was led by M&G Investment Management (part of M&G plc), with further participation from new investors Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others, and existing investors, including Oxford Sciences Innovation. This includes $43m in convertible loan notes previously issued by Vaccitech that converted into Series B shares.
Led by Bill Enright, Chief Executive Officer, Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company provides a proprietary platform that combines modified simian adenoviral vectors (known as ChAdOx1 or ChAdOx2) to prime a targeted immune response with the Modified Vaccinia Ankara virus (MVA) to boost the targeted immune response against cells infected with a virus or tumor cells. Its heterologous prime-boost approach has been demonstrated to drive immune responses, including the leading CD8+ T cell stimulation profile in humans, to date. In addition to the HBV, HPV and prostate cancer programs, Vaccitech’s pipeline includes product candidates targeting infectious disease (including MERS coronavirus and Herpes Zoster) and cancer (including non-small cell lung cancer).
The proceeds from the financing will support the development of three infectious disease and immuno-oncology programs. The programs include:
- A Phase 1/2 clinical trial of VTP-300 in patients with chronic hepatitis B virus (HBV) infection. The first patient in the trial was dosed in February 2021.
- A Phase 1/2 clinical trial of VTP-200 in patients with persistent, high-risk human papillomavirus (HPV) infection.
- A Phase 1/2 clinical trial of VTP-850 in combination with a checkpoint inhibitor in patients with prostate cancer.